On June 6, 2014, the Compensation Committee of the Board of Directors (the “Board”) of Pain Therapeutics, Inc. (NASDAQ:PTIE) approved changes in compensation for the Company’s named executive officers with respect to the officers’ and the Company’s performance from mid-2013 to mid-2014. As a result, the base salary for Remi Barbier, Chairman of the Board, President and Chief Executive Officer, was increased to $800,000 per year from $725,000 per year. The base salary for Nadav Friedmann, Ph.D., M.D., Chief Medical and Operating Officer, was increased to $290,000 per year from $275,000. The base salary for Peter S. Roddy, Vice President and Chief Financial Officer, was increased to $345,000 from $330,000 per year. Pain Therapeutics, Inc. (NASDAQ:PTIE) net profit margin is 72.40% and weekly performance is 12.64%. On last trading day company shares ended up $6.06. Analysts mean target price for the company is $8.00. Pain Therapeutics, Inc. (NASDAQ:PTIE) distance from 50-day simple moving average (SMA50) is 16.25%.
Repligen Corporation (NASDAQ:RGEN) Director Thomas F. Ryan, Jr. sold 10,000 shares of Repligen Corp. stock in a transaction that occurred on Tuesday, June 24th. The stock was sold at an average price of $21.78, for a total value of $217,800.00. Following the transaction, the director now directly owns 50,312 shares in the company, valued at approximately $1,095,795. Repligen Corporation (NASDAQ:RGEN) shares advanced 3.18% in last trading session and ended the day on $22.71. RGEN gross Margin is 64.70% and its return on assets is 15.90%.Repligen Corporation (NASDAQ:RGEN) quarterly performance is 77.15%.
Morristown-based Pernix Therapeutics Holdings Inc. (NASDAQ:PTX) a specialty pharmaceutical company, announced on 23 June that it has appointed Sanjay Patel as chief financial officer. Pernix Therapeutics Holdings Inc. (NASDAQ:PTX) shares moved up 2.00% in last trading session and was closed at $9.17, while trading in range of $8.86 – $9.23. Pernix Therapeutics Holdings Inc. (NASDAQ:PTX) year to date (YTD) performance is 263.89%.
Omeros corporation (NASDAQ:OMER) Director Peter A. Md Demopulos acquired 6,153 shares of the stock in a transaction dated Tuesday, June 24th. The stock was purchased at an average price of $16.20 per share, with a total value of $99,678.60. Following the acquisition, the director now directly owns 181,220 shares in the company, valued at approximately $2,935,764. Omeros Corporation (NASDAQ:OMER) ended the last trading day at $17.35. Company weekly volatility is calculated as 7.79% and price to cash ratio as 11.27.Omeros Corporation (NASDAQ:OMER) showed a positive weekly performance of 22.70%.
AbbVie p Inc. (NYSE:ABBV) roposed to acquire Shire for £20.44 in cash and 0.7988 AbbVie shares per Shire share, reiterating its earlier offer. AbbVie Inc. (NYSE:ABBV) net profit margin is 21.80% and weekly performance is 4.28%. On last trading day company shares ended up $56.51. Analysts mean target price for the company is $56.78. AbbVie Inc. (NYSE:ABBV) distance from 50-day simple moving average (SMA50) is 7.30%.